To access the session recording, navigate to the content tab and click the view video button. 

Session Schedule

Find a specific presentation in the course by navigating to the timestamp indicated below.

0:00:00
Introduction

0:05:45
Expanding knowledge on the global epidemiology of RBD; and update on the Tasmania ISLAND Study on isolated RBD
Jane Alty (Australia)

0:24:40
Neurodegeneration risk in isolated RBD and insights from brain imaging studies
Dario Arnaldi (Italy)

0:45:10
Depression, RBD, neurodegeneration, and familial risk
Yun Kwok Wing (Hong Kong)

1:05:00
Machine learning-based prediction of neurodegeneration and prognostic counseling in iRBD
Ki-Young Jung (Korea, Republic of)

1:22:30
Question and answer

1:31:43
Session end

Summary:

RBD was first formally reported as an Abstract and poster session at the Seattle July 1985 joint meeting of the Sleep Research Society and American Sleep Disorders Association (when the Associated Professional Sleep Society [APSS] was formally organized, with subsequent yearly meetings):

Schenck CH, Bundlie SR, Mahowald MW. Human REM Sleep Chronic Behavior Disorders: A New Category of Parasomnia. Sleep Res 1985: 14:208.

Clinical and basic science research on RBD, along with knowledge about the clinical spectrum of RBD and its comorbidities, its management, and its prognostic implications, has greatly expanded and deepened over the past 40 years, with growing involvement across many countries and five continents, including prominent investigators in Asia, Australia, North America and Europe. So it is timely to present a summary of current knowledge and imminent horizons in RBD clinical care and RBD research at the Singapore WSS 2025 congress. The four speakers will discuss the following topics: the global epidemiology of RBD; the initiation and current status of the novel Tasmanian ISLAND study on isolated RBD (iRBD); the increased neurodegeneration risk in iRBD, and insights from brain imaging studies of iRBD, including the results of an ongoing neuroimaging study (RF-2021-12374240). RBD in psychiatric populations and neurodegenerative risk, along with associated familial risk; and machine learning-based prediction of neurodegeneration and prognostic counseling in iRBD

Learning Objectives:

Upon completion of this CME activity, participants will be able to:
• Critically discuss the epidemiologic data on global prevalence of iRBD and have a deeper understanding of remote diagnostic approaches for RBD
• Gain insight about the strongest risk factors of phenoconversion in iRBD, including the usefulness of brain imaging techniques
• Recognize the clinical and neurodegenerative implications of RBD in psychiatric populations to improve clinical care and future neuroprotection
• Understand recent advances in the prediction of neurodegeneration risk in iRBD using Machine Learning approaches